Sector News

BioAmber Announces New Chief Financial Officer and Change to the Board

January 7, 2015
Life sciences
/PRNewswire/ – BioAmber Inc., an industrial biotechnology company producing sustainable chemicals, today announced that Chief Financial Officer Andrew Ashworth retired on December 31, 2014 and Francois Laurin has been hired to succeed Andrew as the Company’s Chief Financial Officer.  BioAmber also announced today that long-time board member Denis Lucquin had resigned effective December 31, 2014. 
 
Andrew Ashworth is retiring after three and a half years as BioAmber’s CFO, the culmination of a long and distinguished career that previously included senior positions at Genencor/Danisco and VF Corporation.  Andrew was instrumental in preparing BioAmber for its initial public offering, completing the IPO in 2013 and ensuring regulatory compliance since the listing.  Andrew will continue in an advisory role to the Company in the first half of 2015 to ensure a smooth transition.
 
Francois Laurin has been hired to succeed Andrew as Chief Financial Officer.  Francois was most recently the CFO of Alderon Iron Ore Corp (NYSE:AXX, TSX:ADV), a publicly listed exploration and development stage company in the mining sector.  Francois was formerly the CFO of Consolidated Thompson Iron Mines (TSX:CLM), where he played a leading role in the rapid growth of the company and its subsequent sale to Cliffs National Resources for $4.9 billion and prior to that he was the CFO of Transat A.T. (TSX:TRZ).  Francois has also held senior financial positions at Caisse de Depot du Quebec, Bombardier and Teleglobe.  Francois is a chartered professional accountant and a chartered financial analyst, and was named a Fellow CPA in 2014.
 
“Andy has been a valued colleague who’s extensive experience helped guide our IPO efforts.  He will be missed and we wish him the best in his retirement,” said JF Huc, BioAmber CEO.  “I am pleased to welcome Francois Laurin, a seasoned, dynamic CFO with extensive public company experience.  He is a great addition and will help lead BioAmber through our next stage of growth,” he added.
 
Denis Lucquin is the Managing Partner of Sofinnova Partners, a European venture capital firm that led the original investment in BioAmber in 2009.  Denis has been a board member since Sofinnova’s initial investment and he has greatly contributed to the Company’s success.  Denis’ decision to resign was due to his firm’s policy to step down from board memberships following initial public offerings. 
 
“On behalf of the board, I’d like to thank Denis for his many contributions.  His experience in funding start ups and his industry knowledge proved invaluable in guiding BioAmber from a four person start up to a publicly traded company,” said Raymond Land, chairman of the board. 
 
“I am proud to have helped BioAmber become the company it is today, which I believe is on the verge of success in the emerging field of bio-based chemicals,” said Denis Lucquin.
 
Source: BioAmber 

Related News

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]

September 15, 2020

Gilead to buy Immunomedics for $21bn

Life sciences

Gilead Sciences has announced plans to acquire Immunomedics in a deal valued at $21 billion. Under the agreement, which has been unanimously approved by both boards of directors, Gilead will […]